AKTX - Akari Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

18.85B

Cash

3.845M

Avg Qtr Burn

-4.108M

Short % of Float

Insider Ownership

17.91%

Institutional Own.

1.61%

Qtr Updated

12/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nomacopan Details Paroxysmal nocturnal hemoglobinuria	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nomacopan Details Hematopoietic stem cell transplantation thrombotic microangiopathies	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nomacopan Details COVID-19	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nomacopan Details Atopic Keratoconjunctivitis	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nomacopan Details Bullous pemphigoid	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.